Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAC vs SAPT After TAVR
NCT05375474Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of warfarin in bioprosthetic valve thrombosis (BPVT) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoints: Composite of all-cause mortality, myocardial infarction, stroke, TIA, peripheral artery thrombosis, intracardiac thrombosis, major bleeding, and disabling/life-threatening bleeding at 1 year and Rates of bioprosthetic valve thrombosis detected by 4D-CT. Started Jul 2023; status: recruiting.
02
Drugs
warfarin
03
Conditions
bioprosthetic valve thrombosis (BPVT)
Beyond the preview
Go deeper on NCT05375474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375474.